apatinib: reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 45139106 |
| CHEMBL ID | 3545414 |
| SCHEMBL ID | 21847695 |
| MeSH ID | M0551682 |
| Synonym |
|---|
| HY-13342 |
| apatinib |
| BCP9000308 |
| tk02x14asj , |
| 1218779-75-9 |
| unii-tk02x14asj |
| 3-pyridinecarboxamide, n-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-, methanesulfonate (1:1) |
| yn-968d1 |
| yn 968d1 |
| yn968d1 |
| CS-0694 |
| S2221 |
| smr004703036 |
| MLS006011286 |
| rivoceranib mesylate [who-dd] |
| rivoceranib mesylate [usan] |
| apatinib mesylate |
| n-[4-(1-cyanocyclopentyl)phenyl]-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide monomethanesulfonate salt |
| rivoceranib mesylate |
| AC-35390 |
| n-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide methanesulfonate |
| DTXSID80153427 |
| CHEMBL3545414 |
| apatinib (registered name in china) |
| AKOS026750547 |
| HMS3655H12 |
| bdbm50152828 |
| SW220296-1 |
| n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;methanesulfonic acid |
| n-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide mesylate |
| apatinib?mesylate |
| n-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide mesylate |
| n-(4-(1-cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)pyridine-3-carboxamide mesylate |
| BCP15234 |
| rivoceranib mesylate (usan) |
| D11289 |
| alitan (tn) |
| SB16589 |
| CCG-269641 |
| 3-pyridinecarboxamide, n-[4-(1-cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-, methanesulfonate (1:1) |
| apatinib-yn968d1 |
| SCHEMBL21847695 |
Apatinib is a novel, oral, small-molecule tyrosine kinase inhibitor that mainly targets vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit angiogenesis. Apatinib is widely used for the treatment of glioma.
Apatatinib has a concentration-dependent effect on the small cell lung cancer cell line NCI-H446. Apatinib also has a significant inhibitory effect on metastasis and invasion of liver cancer cells.
Apatini has been shown to clinically enhance anti-PD-1 immunotherapy for advanced gastric cancer (GC) Apatinib has been found to have promising efficacy and manageable adverse effects for the treatment of solid tumours.
Apatinib could inhibit the expression of MDR1 and the activity of the ERK signaling pathway in a dose-dependent manner. Apatinib can inhibit the invasion and migration of lung adenocarcinoma cells H1299 and H3255.
Apatinib treatment strengthened the anti-tumor influence of cisplatin on TPC-1 cells through downregulating p-VEGFR2, p-Akt and p-mTOR. Apatinib is a new treatment option for advanced gastric cancer.
The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. Apatinib is well tolerated, and its most common adverse effects include hand- foot syndrome, hypertension,. proteinuria and neutropenia. Grades 3 and 4 adverse events were neutropania, hypertension and leukopenia.
The validated method was successfully applied to a clinical pharmacokinetic study following oral administration of 500 mg apatinib mesylate in patients with advanced colorectal cancer. Owing to the risk of drug-drug interactions based on CYP3A4/CYP2C9 inhibition, caution is advised in the concurrent use of Apatinib with either CYP2 C9 or CYP 3A4 substrates.
Apatinib combined with S-1 was not superior to other chemotherapy regimens as first-line therapy for advanced gastric cancer. PD-1 inhibitors in combination with apatinib may help improve treatment outcomes and increase survival benefits.
Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR-2), is an orally bioavailable agent. Patients with tracheal and esophageal fistulas can take crushed apatinib by nutrient tube.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), is an orally bioavailable agent currently being studied in multiple tumor types." | ( Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Jimeno, A; Messersmith, WA; Scott, AJ, 2015) | 2.77 |
| " Apatinib, a small molecule inhibitor of vascular endothelial growth factor receptor (VEGFR-2), is an orally bioavailable agent, which has shown survival benefit in multiple solid tumors." | ( Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial. Feng, YY; Zhang, Q; Zhou, H; Zhou, JG; Zhou, NJ, 2018) | 2.83 |
| " Patients with tracheal and esophageal fistulas can take crushed apatinib by nutrient tube, with the same bioavailability and efficacy." | ( Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study. Chen, C; Feng, H; Liu, D; Pan, Z; Pang, Q; Ren, P; Shang, X; Tang, P; Tao, YZ; Yanwei, L; Yue, J; Zhang, W, 2020) | 1.11 |
| "Although drug combination has proved to be an efficient strategy for clinic gastric cancer therapy, how to further improve their bioavailability and reduce the side effects are still challenges due to the low solubility and untargeted ability of drugs." | ( A hybrid membrane coating nanodrug system against gastric cancer Fan, J; Liu, B; Long, Y; Tong, C; Wang, Z; Yuan, L; Zhao, Y, 2021) | 0.62 |
| " The objective of the study was to evaluate the effect of food on bioavailability as well as single- and multiple-dose pharmacokinetics (PKs) of 81 and 201 mg doses of rivoceranib." | ( Effect of food intake on the pharmacokinetics of rivoceranib in healthy subjects. Koplowitz, B; McGinn, A; Park, CH; Pesco-Koplowitz, L; Sachar, M, 2022) | 0.72 |
| " Patients with nondigestive system cancer had higher apparent volume of distribution and absorption rate constant than digestive system cancer." | ( Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients. Chen, KG; Guo, ZX; Kan, M; Li, Q; Li, Y; Liu, HY; Liu, XL; Shi, JY; Song, LL; van den Anker, J; Yang, XM; Ye, PP; Zhang, YH; Zhao, FR; Zhao, W, 2023) | 1.16 |
Apatinib is effective and well tolerated in patients with advanced NSCLC. Dosing of apatinib in various cancer subpopulations may require adjustments to optimize efficacy and benefits.
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 (µMol) | 0.0010 | 0.0000 | 0.4830 | 8.8000 | AID1288431 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1288431 | Inhibition of VEGF2 receptor (unknown origin) by ELISA | 2016 | Bioorganic & medicinal chemistry, May-01, Volume: 24, Issue:9 | Synthetic approaches to the 2014 new drugs. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 224 (41.03) | 24.3611 |
| 2020's | 322 (58.97) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (47.77) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 109 (18.96%) | 5.53% |
| Reviews | 57 (9.91%) | 6.00% |
| Case Studies | 113 (19.65%) | 4.05% |
| Observational | 16 (2.78%) | 0.25% |
| Other | 280 (48.70%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Camrelizumab Plus Apatinib as Maintenance Treatment in Extensive-stage SCLC With a Response or Stable Disease After Standard Chemotherapy: A Single-arm, Prospective Clinical Trial [NCT04901754] | Phase 2 | 38 participants (Anticipated) | Interventional | 2021-07-14 | Recruiting | ||
| Intensity Modulated Radiation Therapy Combined With Apatinib for Inoperable or Iodine Refractory Thyroid Cancer: A Phase II Single-arm Study [NCT03300765] | Phase 2 | 20 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| Evaluating the Efficacy and Safety of Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer [NCT03942068] | Phase 2 | 35 participants (Anticipated) | Interventional | 2019-09-01 | Not yet recruiting | ||
| Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Bevacizumab in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: A Prospective, Single-Center, Phase II Study [NCT05400902] | Phase 2 | 17 participants (Anticipated) | Interventional | 2023-05-31 | Recruiting | ||
| Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer:a Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study [NCT01287962] | Phase 3 | 480 participants (Anticipated) | Interventional | 2011-04-30 | Active, not recruiting | ||
| Phase II Clinical Study of the Combination of Apatinib and PD1 in Treating Advanced Gastric Cancer [NCT03954756] | Phase 2 | 35 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| Phase II Study on the Second-line Treatment of Gastric Adenocarcinoma With Apatinib Combined With POF(Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) [NCT03788174] | Phase 2 | 26 participants (Anticipated) | Interventional | 2019-02-01 | Recruiting | ||
| Phase Ⅱ Study of Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer [NCT03775928] | Phase 2 | 80 participants (Anticipated) | Interventional | 2018-12-18 | Recruiting | ||
| Neoadjuvant Camrelizumab Plus Apatinib or Platinum-based Chemotherapy for Potentially Resectable (Resectable and Initially Unresectable) II-III Non-small Cell Lung Cancer [NCT04379739] | Phase 2 | 89 participants (Actual) | Interventional | 2020-07-26 | Active, not recruiting | ||
| A Single-center Study of the Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma [NCT05760430] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-12-14 | Recruiting | ||
| Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Recurrent or Metastatic Triple-negative Breast Cancer: a Double-blinded Randomized Controlled Clinical Trial [NCT03932526] | Phase 2 | 184 participants (Anticipated) | Interventional | 2019-06-24 | Not yet recruiting | ||
| Apatinib Combined With Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma Who Failed at Least the First-line Treatment [NCT04586088] | Phase 2 | 58 participants (Actual) | Interventional | 2020-05-05 | Active, not recruiting | ||
| A Multicentre, Open-parallel, Randomized, Controlled Phase Ⅲ Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Unresectable Locally Advanced or Metastatic Triple Negative Bre [NCT04335006] | Phase 3 | 80 participants (Actual) | Interventional | 2020-07-14 | Terminated(stopped due to Sponsor R & D Strategy Adjustment) | ||
| Prospective,Single-arm,and Exploratory Phase II Clinical Study for the Efficacy of Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Squamous Cell Carcinoma After Radical Resection [NCT03913182] | Phase 2 | 39 participants (Anticipated) | Interventional | 2019-04-02 | Recruiting | ||
| SCAFIGC：Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial [NCT05942573] | Phase 2 | 107 participants (Anticipated) | Interventional | 2022-12-24 | Recruiting | ||
| A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer [NCT03889626] | Phase 3 | 242 participants (Anticipated) | Interventional | 2019-03-22 | Not yet recruiting | ||
| Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (LANCET): A Multicenter, Single-arm, Phase II Trial [NCT03243838] | Phase 2 | 31 participants (Actual) | Interventional | 2018-08-01 | Completed | ||
| Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture [NCT03925233] | 300 participants (Anticipated) | Observational | 2019-01-02 | Enrolling by invitation | |||
| Phase I/IIa, Single-Arm, Open Study of Apatinib and MASCT in Patients With Advanced Solid Tumors [NCT02844881] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| A Single-Institutional Phase IIa Trial and A Multi-Institutional Phase IIb Trial of Apatinib in Metastatic Triple-Negative Breast Cancer [NCT01176669] | Phase 2 | 60 participants (Anticipated) | Interventional | 2010-06-30 | Completed | ||
| A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma [NCT03857763] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-03-01 | Not yet recruiting | ||
| Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma [NCT05189184] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-03-30 | Not yet recruiting | ||
| Preoperative Intensity-modulated Radiotherapy (IMRT) With Concurrent Apatinib Mesylate for Localised Extremity or Trunk Sarcoma [NCT05235100] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | ||
| Neoadjuvant Apatinib Added to Weekly Paclitaxel and Cisplatin in Patient With Locally Advanced or Early Stage HER2 Negative Breast Cancer (APP) : a Open-label, Randomized, Controlled, Trial [NCT03982485] | Phase 2 | 196 participants (Anticipated) | Interventional | 2018-10-16 | Recruiting | ||
| Phase I Study of the Combination of Apatinib and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) [NCT03244774] | Phase 1 | 18 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy With or Without Chemotherapy [NCT02874651] | Phase 2 | 25 participants (Actual) | Interventional | 2016-10-31 | Terminated(stopped due to Unacceptable toxicity (nasopharynx necrosis and massive hemorrhage)) | ||
| Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis [NCT03229096] | Phase 2 | 35 participants (Anticipated) | Interventional | 2017-02-01 | Recruiting | ||
| Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above [NCT03725423] | Phase 4 | 50 participants (Anticipated) | Interventional | 2018-10-31 | Not yet recruiting | ||
| A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations [NCT03634059] | 80 participants (Anticipated) | Interventional | 2018-08-15 | Not yet recruiting | |||
| Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer [NCT03144856] | Phase 2 | 39 participants (Anticipated) | Interventional | 2017-02-22 | Recruiting | ||
| A Prospective, One-arm Open Clinical Trial of Apatinib Combined With Albumin Paclitaxel and Carboplatin as a Neoadjuvant Therapy for the Safety and Efficacy of Triple-negative Breast Cancer [NCT03650738] | Phase 2 | 60 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| Fluzoparib Combined With Apatinib for the Treatment of Carrying TP53 Harmful Mutations in Advanced Refractory Solid Tumors of the I Stage Clinical Study [NCT03645200] | Phase 1 | 60 participants (Anticipated) | Interventional | 2019-07-01 | Not yet recruiting | ||
| Phase II Study of the Combination of Apatinib and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) [NCT03707639] | Phase 2 | 26 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | ||
| Apatinib+Ifosfamide and Etoposide (IE) Versus IE Alone for Relapsed or Refractory Osteosarcoma: a Real-world Study in Two Centers in China [NCT04690231] | 79 participants (Actual) | Interventional | 2020-12-01 | Completed | |||
| An Open-lable, Single Arm, Single Center, Phase 2 Study of PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell [NCT03701022] | Phase 2 | 61 participants (Anticipated) | Interventional | 2018-10-20 | Not yet recruiting | ||
| A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic Therapy（Chemotherapy and/or Targeted Therapy） [NCT02329860] | Phase 3 | 400 participants (Actual) | Interventional | 2014-01-13 | Completed | ||
| A Single Arm,Open Clinical Study of Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies [NCT03654612] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2018-10-16 | Recruiting | ||
| A Phase II , Open-label , Investigator-initiated Trail of An Anti-PD-1 Inhibitor SHR-1210 in Combination With Apatinib in Patients With Unresectable Hepatocellular Carcinoma [NCT03793725] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-01-30 | Not yet recruiting | ||
| Apatinib Dose Titration: Analyses of Exposure, Safety and Efficacy in Advanced or Metastatic Gastric Cancer [NCT02764268] | 60 participants (Actual) | Interventional | 2016-11-02 | Completed | |||
| A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer [NCT03547804] | Phase 2 | 31 participants (Actual) | Interventional | 2018-05-31 | Completed | ||
| SHR-1210, a Novel Anti-PD-1 Antibody, in Combination With Apatinib and Irinotecan/Paclitaxel Liposome Plus Nedaplatin in Patients With Previously Untreated Advanced or Metastatic Esophageal Squamous Cell Cancer: a Phase II Study [NCT03603756] | Phase 2 | 45 participants (Anticipated) | Interventional | 2018-07-31 | Recruiting | ||
| Apatinib Combined With Cisplatin and Paclitaxel as First-line Chemotherapy for Recurrent or Persistent Advanced Cervical Cancer: A Single Arm, Single Center, Open, Phase II Trial [NCT04188847] | Phase 2 | 37 participants (Actual) | Interventional | 2019-12-06 | Completed | ||
| A Single Arm, Exploratory, Multicenter Clinical Study of Fluzopari Combined With Apatinib Neoadjuvant Therapy in Patients With Advanced Non R0 Resectable Ovarian Cancer [NCT05597527] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-11-01 | Not yet recruiting | ||
| Three-arm Open Parallel Control Phase II Trial for Evaluation of Thermal Ablation Combined With Apatinib and PD-1 Antibody SHR-1210 for Advanced Liver Cancer [NCT04204577] | Phase 2 | 90 participants (Anticipated) | Interventional | 2019-11-01 | Recruiting | ||
| Apatinib Plus Sintilimab in Patients With Advanced Gastric Cancer [NCT04089657] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children [NCT03868852] | Phase 1/Phase 2 | 48 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| A Randomized, Multicenter, Open-Label, Phase 3 Study Comparing the Efficacy and Safety of SHR-1210 Plus Capecitabine and Oxaliplatin Sequenced by Apatinib With or Without SHR-1210 Versus Capecitabine and Oxaliplatin in Subjects With Previously Untreated A [NCT03813784] | Phase 3 | 887 participants (Actual) | Interventional | 2019-03-07 | Active, not recruiting | ||
| The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) [NCT03811054] | Phase 2 | 60 participants (Anticipated) | Interventional | 2018-12-01 | Recruiting | ||
| Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer [NCT03777124] | Phase 2 | 230 participants (Anticipated) | Interventional | 2019-02-28 | Not yet recruiting | ||
| The Efficacy and Safety of Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer :Single Arm, Phase II Clinical Trail [NCT03735082] | Phase 2 | 29 participants (Anticipated) | Interventional | 2018-11-01 | Recruiting | ||
| A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC) [NCT05447702] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | ||
| A Phase II Study of Efficacy and Safety of Combination of Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer [NCT05932264] | Phase 2 | 60 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| Efficacy and Safety of Conversion Therapy With Sintilimab in Combination With Chemotherapy and Apatinib in Patients With Stage IV Gastric Cancer [NCT04267549] | Phase 2 | 47 participants (Actual) | Interventional | 2019-05-01 | Active, not recruiting | ||
| A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells [NCT03718624] | Phase 2 | 36 participants (Anticipated) | Interventional | 2018-10-30 | Not yet recruiting | ||
| A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer [NCT02529878] | Phase 2 | 30 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Efficacy and Safety of Camrelizumab (SHR-1210) With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer: a Single-Arm, Phase II Study [NCT04506242] | Phase 2 | 74 participants (Anticipated) | Interventional | 2020-09-15 | Not yet recruiting | ||
| Tianjin Medical University Cancer Institute and Hospital [NCT03348098] | Phase 2 | 20 participants (Anticipated) | Interventional | 2017-09-06 | Recruiting | ||
| Neoadjuvant Personalized Anti-PD-1 Therapy With Combination of Anti-VEGFR Therapy in Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Randomized Controlled Phase II Trial [NCT05069857] | Phase 2 | 46 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | ||
| Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial [NCT04393506] | Phase 1 | 21 participants (Actual) | Interventional | 2020-04-23 | Completed | ||
| Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor [NCT04282278] | Phase 2 | 180 participants (Anticipated) | Interventional | 2020-07-16 | Recruiting | ||
| A Multicenter, Prospective, Double-Cohort Phase II Clinical Study of Camrelizumab in Combination With Docetaxel and Platinum or Apatinib Mesylate as First-Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [NCT05156970] | Phase 2 | 178 participants (Anticipated) | Interventional | 2021-06-24 | Recruiting | ||
| Camrelizumab in Combination With Apatinib in in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma: a Phase Ib/II, Multicentre, Open-label, Single-arm Trial [NCT04476459] | Phase 1/Phase 2 | 33 participants (Anticipated) | Interventional | 2020-07-23 | Recruiting | ||
| Phase II Study of Apatinib as Third- or Further-line Treatment for Patients With Extensive Stage Small Cell Lung Cancer [NCT02945852] | Phase 2 | 40 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| A Phase 1/2 Study of Apatinib in Combination With AP(Pemetrexed/Cisplatin) or AC(Pemetrexed/Carboplatin) as First-line Chemotherapy for Advanced Epidermal Growth Factor Receptor(EGFR) Wild Type Non-squamous Non-small Cell Lung Cancer [NCT03201146] | Phase 1/Phase 2 | 48 participants (Anticipated) | Interventional | 2017-06-27 | Recruiting | ||
| An Open-Label, Multi-Center, Phase II Study to Evaluate the Efficacy and Safety of PD-1 Antibody Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative MSS Advanced or Metastatic GC or GEJ Cancer [NCT05216237] | Phase 2 | 31 participants (Anticipated) | Interventional | 2022-02-15 | Recruiting | ||
| Study Evaluating the Safety and Efficacy of FOLFOX Plus Apatinib or FOLFIRI Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer [NCT03193814] | Phase 2 | 50 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
| A Prospective, Open-label, Randomized Controlled Clinical Study of Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma [NCT03193424] | Phase 2 | 120 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| A Single Arm, Open Label, Multicenter Exploratory Study of Apatinib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Second Line Therapy [NCT03190616] | Phase 2 | 54 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma [NCT03180476] | Phase 2 | 21 participants (Actual) | Interventional | 2017-04-01 | Completed | ||
| A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanc [NCT03042611] | Phase 3 | 460 participants (Actual) | Interventional | 2017-03-14 | Completed | ||
| A Randomized Clinical Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus [NCT03520257] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-05-01 | Not yet recruiting | ||
| A Single-center Open, Randomized, Controlled Study to Compare the Apapitatin Combined With SOX and SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma [NCT03702491] | Phase 2 | 138 participants (Anticipated) | Interventional | 2018-08-10 | Recruiting | ||
| Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer [NCT03662035] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-09-15 | Not yet recruiting | ||
| Efficacy and Safety of Apatinib Combined With Dose-dense Temozolomide in Recurrent Glioblastoma [NCT03660761] | Phase 2 | 25 participants (Actual) | Interventional | 2016-03-03 | Completed | ||
| Clinical Study of Apatinib Mesylate Combined With Stereotactic Body Radiation Therapy in the Treatment of Oligometastasis of Breast Cancer [NCT03457467] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-03-15 | Not yet recruiting | ||
| A Phase 2 Study of Apatinib Combined With Temozolomide in the Treatment of Advanced Melanoma Patients After Conventional Treatment Failure [NCT03422445] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | ||
| A Study of Apatinib in Combination With Chemotherapy Versus Chemotherapy Alone for Advanced Ovarian Cancer [NCT03393507] | Phase 2 | 34 participants (Anticipated) | Interventional | 2017-08-01 | Recruiting | ||
| A Phase II, Open-labeled, Randomised, Non-comparative, Two-arms Investigator-initiated Clinical Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib in Subjects With Advanced Triple Negative Breast Cancer [NCT03394287] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-10 | Completed | ||
| A Single-Arm Phase II Clinical Trial of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma [NCT03376737] | Phase 2 | 120 participants (Anticipated) | Interventional | 2017-10-12 | Recruiting | ||
| Camrelizumab and Apatinib Combined With Chemotherapy (mFOLFOX6) in Neoadjuvant Therapy for Locally Advanced Colon Cancer [NCT04625803] | Phase 2 | 64 participants (Anticipated) | Interventional | 2021-01-04 | Recruiting | ||
| A Single Arm Exploratory Study of Chemotherapy Plus Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Locally Advanced Esophageal Squamous Cell Carcinomas [NCT03671265] | 20 participants (Anticipated) | Interventional | 2018-09-17 | Recruiting | |||
| Evaluation of the Safety, Pharmacokinetics and Efficacy of Four Doses of YN968D1 in Subjects With Solid Tumors [NCT01497704] | Phase 1/Phase 2 | 55 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Phase II Randomized Controlled Trial of Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab in Third-line or Later-line Treatment of Advanced Gastric Adenocarcinoma [NCT05095636] | Phase 2 | 102 participants (Anticipated) | Interventional | 2021-03-17 | Recruiting | ||
| A Multicenter, Single-arm, Phase Ⅱ Clinical Trial of Apatinib Monotherapy in Elderly Patients With Advanced Gastric Cancer(GC) [NCT03104283] | Phase 2 | 48 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| the Effectiveness and Safety Study on Apatinib Combined With Vinorelbine Used for Driver Gene Mutation Negative Third-line and Third-line Post Progression Advanced Non-small Cell Lung Cancer [NCT03652857] | Phase 2 | 30 participants (Actual) | Interventional | 2017-01-01 | Completed | ||
| Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer: A Randomized Controlled Clinical Trial [NCT03651219] | Phase 3 | 90 participants (Anticipated) | Interventional | 2018-09-08 | Not yet recruiting | ||
| Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization [NCT03510416] | Phase 2 | 22 participants (Anticipated) | Interventional | 2018-05-01 | Not yet recruiting | ||
| A Multicenter, Phase II Clinical Study of Adjuvant Apatinib After IMRT With Concurrent Chemotherapy Versus IMRT With Concurrent Chemotherapy in High-risk Metastasis of Nasopharyngeal Carcinoma [NCT03612219] | Phase 2 | 240 participants (Anticipated) | Interventional | 2018-07-01 | Recruiting | ||
| A Non-randomized Phase II Study of Apatinib Mesylate Tablets Plus Tegafur Gimeracil Oteracil Potassium Capsules in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck [NCT03096184] | Phase 2 | 38 participants (Anticipated) | Interventional | 2016-12-23 | Active, not recruiting | ||
| Apatinib Combined Capecitabine Versus Capecitabine Alone for Adjuvant Therapy in Patients After Biliary Carcinoma Surgery: a Prospective Randomized Controlled Study [NCT03609489] | Phase 2 | 40 participants (Anticipated) | Interventional | 2018-09-10 | Not yet recruiting | ||
| Clinical Study of Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of Extensive Stage Small Cell Lung Cancer [NCT05001412] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-01-27 | Recruiting | ||
| A Randomized, Multicenter, Noncomparative Clinical Study of Fluzoparib With or Without Apatinib for Maintenance Therapy in PARPi-pretreated Platinum-sensitive Recurrent Ovarian Cancer [NCT06161272] | Phase 2 | 80 participants (Anticipated) | Interventional | 2023-12-10 | Not yet recruiting | ||
| A Phase II Trial of Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck: the RASS Study [NCT03539172] | Phase 2 | 61 participants (Anticipated) | Interventional | 2018-06-01 | Not yet recruiting | ||
| A Prospective Single-arm Phase II Clinical Study to Evaluate the Efficacy of Camrelizumab in Combined With APatinib and Albumin Paclitacxel in Advanced Untreated EGFR Wild Type and ALK-negative Lung Adenocarcinoma [NCT04459078] | Phase 2 | 63 participants (Anticipated) | Interventional | 2020-08-26 | Active, not recruiting | ||
| A Retrospective Clinical Study of Postoperative Concurrent Chemoradiotherapy Combined With Anti-angiogenic Drugs in the Treatment of Glioblastoma. [NCT03567135] | 60 participants (Anticipated) | Observational | 2017-10-01 | Recruiting | |||
| A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib For First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) [NCT04950400] | 60 participants (Anticipated) | Interventional | 2021-07-07 | Not yet recruiting | |||
| A Phase II Study of PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma [NCT03955354] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-03-05 | Recruiting | ||
| Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Single-arm, Phase 2 Trial [NCT04824352] | Phase 2 | 44 participants (Anticipated) | Interventional | 2021-04-01 | Recruiting | ||
| Phase II Study of Apatinib in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer [NCT03129698] | Phase 2 | 52 participants (Anticipated) | Interventional | 2017-04-11 | Recruiting | ||
| Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma: a Randomized, Open-label, Parallel, Multicenter Trial [NCT05613478] | Phase 3 | 130 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| A Single-arm, Open, Prospective, Single-center, Phase Ⅱ Clinical Study of Carilizumab Combined With Apatinib in theTtreatment of Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma and Alveolar Soft Tissue Sarcoma [NCT04447274] | Phase 2 | 20 participants (Anticipated) | Interventional | 2020-07-01 | Not yet recruiting | ||
| A Randomized, Parallel-controlled, Exploratory Clinical Trial of Second-line Chemotherapy With Second-line Chemotherapy Versus Second-line Chemotherapy With Apatinib in the Treatment of Metastatic Colorectal Cancer [NCT03412994] | Phase 2 | 60 participants (Anticipated) | Interventional | 2018-02-28 | Not yet recruiting | ||
| Clinical Study of Apatinib Mesylate in the Treatment of Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy. [NCT03546855] | Phase 2 | 69 participants (Anticipated) | Interventional | 2018-06-01 | Not yet recruiting | ||
| An One Arm, Open and Prospective Studyof Apatinib for the Treatment of Recurrent or Recurrent High-grade Glioma [NCT03390062] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-01-04 | Not yet recruiting | ||
| Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study [NCT03376958] | Phase 4 | 32 participants (Actual) | Interventional | 2017-01-01 | Completed | ||
| The Prospective,Single Arm, Exploratory Clinical Trial of Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-Small-cell Lung Cancer [NCT03356600] | Phase 2 | 44 participants (Anticipated) | Interventional | 2017-12-31 | Not yet recruiting | ||
| Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial [NCT03359018] | Phase 2 | 43 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| The Effectivity and Toxicity of Apatinib for Unresectable Advanced Chondrosarcoma: a Multicentric Retrospective Study [NCT04260113] | 40 participants (Actual) | Interventional | 2019-10-01 | Completed | |||
| Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer Treated With 4 Cycles Chemotherapy Valued as Stable Disease (SD) [NCT03950141] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| A Single-arm，Open Lable Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） [NCT04453930] | Phase 2 | 60 participants (Anticipated) | Interventional | 2020-06-08 | Recruiting | ||
| A Biomarker Driven, Open Label, Phase II Study of VEGFR2 Inhibitor Apatinib in Patients With Recurrent or Refractory Advanced Bone and Soft Tissue Sarcoma [NCT04072042] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-08-31 | Recruiting | ||
| An Exploratory Study of Low-dose Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer [NCT03129256] | Phase 2 | 52 participants (Actual) | Interventional | 2016-12-01 | Completed | ||
| Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma [NCT03709953] | Phase 2 | 33 participants (Anticipated) | Interventional | 2018-10-19 | Recruiting | ||
| A Randomized Controlled Clinical Trial of Apatinib Combined With CHOP Regimen in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma [NCT03631862] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-09-01 | Recruiting | ||
| Phase II Trial of Maintenance Apatinib After Second-Line Treatment for Locally Recurrent or Metastatic Nasopharyngeal Carcinoma [NCT03130270] | Phase 2 | 29 participants (Actual) | Interventional | 2017-01-01 | Active, not recruiting | ||
| A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Patients Who Progressed After First Line EGFR-TKI Treatment Without T790M Mutation [NCT03758677] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-08-01 | Not yet recruiting | ||
| Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma [NCT03398122] | 248 participants (Anticipated) | Interventional | 2017-11-14 | Recruiting | |||
| Study of Apatinib in Patients With Local Advanced/Metastatic Iodine-131（131I）-Refractory/Resistant Differentiated Thyroid Cancer [NCT02731352] | Phase 2 | 20 participants (Actual) | Interventional | 2016-03-11 | Completed | ||
| A Study of Camrelizumab Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer:One-arm, Single-center, Open-stage Phase II Clinical [NCT03912857] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-12-01 | Recruiting | ||
| A Real World Study of Efficacy and Safety for Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer [NCT03377842] | Phase 2 | 100 participants (Anticipated) | Interventional | 2018-01-31 | Not yet recruiting | ||
| Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [NCT02525237] | Phase 2 | 30 participants (Anticipated) | Interventional | 2015-08-31 | Not yet recruiting | ||
| Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer With Extrahepatic Metastasis [NCT04523662] | Phase 2 | 27 participants (Anticipated) | Interventional | 2020-08-30 | Not yet recruiting | ||
| A Randomized, Multicenter, Controlled Study of XELOX (Oxaliplatin With Capecitabine) Combined With Apatinib Versus XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma With D2 Dissection. [NCT03355612] | Phase 3 | 456 participants (Anticipated) | Interventional | 2017-12-20 | Not yet recruiting | ||
| A Single-arm, Prospective Clinical Study of Camrelizumab Combined With Apatinib Mesylate in the Treatment of Relapsed Platinum-resistant Epithelial Ovarian Cancer [NCT04507750] | 40 participants (Anticipated) | Interventional | 2020-08-10 | Recruiting | |||
| Mesylate Apatinib for Stage Ⅳ Soft Tissue Sarcoma Patients After Failure of Traditional Chemotherapy: Prospective, Open-label, Single-Arm, Multi-center Phase II Clinical Trial [NCT03121846] | Phase 2 | 80 participants (Anticipated) | Interventional | 2017-05-01 | Recruiting | ||
| An Open Single Arm Exploratory Study of Apatinib Mesylate Tablets in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer [NCT03344614] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| A Single Arm Pilot Study of Programmed Cell Death Drotein 1 Antibody (PD-1） SHR-1210 Combined With Apatinib Mesylate in Patients With Intermediate And Advanced-Stage Hepatocellular Carcinoma After Radical Hepatectomy [NCT03722875] | 45 participants (Anticipated) | Interventional | 2018-12-01 | Recruiting | |||
| Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open [NCT03792503] | Phase 4 | 20 participants (Anticipated) | Interventional | 2019-02-28 | Not yet recruiting | ||
| An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib in Patients With Recurrent Ovarian Cancer or Triple Negative Breast Cancer [NCT03075462] | Phase 1 | 98 participants (Actual) | Interventional | 2017-03-09 | Completed | ||
| An Open-labeled, Single-arm, Investigator-initiated Phase II Trial of Camrelizumab (Anti-PD-1 Antibody) in Combination With Apatinib and Eribulin in Patients With Advanced Triple-Negative Breast Cancer [NCT04303741] | Phase 2 | 46 participants (Anticipated) | Interventional | 2020-03-25 | Active, not recruiting | ||
| A Phase II Study of Apatinib for Patients With Heavily Pretreated, Metastatic Esophageal Cancer. [NCT02544737] | Phase 2 | 29 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| Clinical Study of Apatinib Mesylate Tablets Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR Wild-type, Non-squamous, Non-small-cell Lung Cancer [NCT02852798] | 60 participants (Anticipated) | Observational | 2016-08-31 | Not yet recruiting | |||
| Effect and Safety of Apatinib on Radiation-Induced Brain Injury: an Open-label, Single-arm, Phase 2 Study. [NCT04152681] | Phase 2 | 36 participants (Anticipated) | Interventional | 2019-10-17 | Recruiting | ||
| Phase I / II Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in the Second-line Treatment of Advanced Gastric Cancer [NCT04286711] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2020-03-31 | Not yet recruiting | ||
| Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer: One-arm Exploratory Clinical Study [NCT04202978] | Phase 1/Phase 2 | 23 participants (Anticipated) | Interventional | 2020-03-01 | Recruiting | ||
| A Real World Study of Camrelizumab Combined With Apatinib Mesylate in Solid Tumors [NCT05380986] | 500 participants (Anticipated) | Interventional | 2022-05-20 | Recruiting | |||
| A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer [NCT02863367] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-08-31 | Not yet recruiting | ||
| A Multicenter, Randomized,Double-Blind Study of Gefitinib in Combination With Apatinib or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Advanced Non-squamous Non-Small-Cell Lung Cancer [NCT02824458] | Phase 3 | 246 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer [NCT02780778] | Phase 2/Phase 3 | 20 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| The Effectiveness and Safety of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma: a Phase 2 Trial. [NCT03167385] | Phase 2 | 20 participants (Anticipated) | Interventional | 2017-03-22 | Recruiting | ||
| Phase II Single Arm Study of Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer [NCT03535961] | Phase 2 | 32 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Apatinib in Combination With CDK4/6 Inhibitor and Endocrine Therapy as the First-line Therapy for HR+/ HER2-Advanced Breast Cancer [NCT05759572] | Phase 2 | 145 participants (Anticipated) | Interventional | 2023-02-01 | Recruiting | ||
| Prospective, Multicenter, Non-intervention Clinical Trial of Apatinib in the Treatment of Advanced Non-squamous，Non-small Cell Lung Cancer [NCT03376191] | 100 participants (Anticipated) | Observational | 2017-05-01 | Recruiting | |||
| Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma：a Randomized, Open-label, Parallel, Multicenter Trial [NCT04521153] | 290 participants (Anticipated) | Interventional | 2021-03-25 | Recruiting | |||
| A Study of Conversion Therapy Using Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) and Systemic Oxaliplatin/S1 Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer [NCT03349827] | 20 participants (Actual) | Interventional | 2018-01-05 | Terminated(stopped due to No enrolled patients received the second surgery.) | |||
| [NCT02510469] | Phase 2/Phase 3 | 48 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| A Prospective, Multicenter, Randomized Controlled Trial of Apatinib Combined With Radiotherapy in Patient With Brain Metastases From Drive Gene Negative NSCLC [NCT03801200] | Phase 2 | 90 participants (Anticipated) | Interventional | 2020-09-10 | Enrolling by invitation | ||
| A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer [NCT05192798] | Phase 2 | 128 participants (Anticipated) | Interventional | 2022-01-14 | Recruiting | ||
| A Single-arm, Prospective Study of Camrelizumab Combined With Apatinib, Etoposide and Cisplatin in First-line Treatment of Extensive Small-cell Lung Cancer. [NCT04490421] | Phase 3 | 45 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | ||
| Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: A Multicenter, Randomized Phase II-III Trial [NCT04208347] | Phase 2/Phase 3 | 580 participants (Anticipated) | Interventional | 2019-12-18 | Active, not recruiting | ||
| Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer [NCT03262545] | Phase 2 | 60 participants (Anticipated) | Interventional | 2017-08-27 | Recruiting | ||
| A Phase I Dose Escalation Clinical Trial of Apatinib Tablets Plus Docetaxel as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma [NCT03071042] | Phase 1 | 12 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| A Single-center, Open-Label, Drug Interaction Study to Determine the Effects of Apatinib on the Metabolism of CYP3A4/5 and CYP2C9 Probe Drugs in Patients With Solid Tumors [NCT03245307] | Phase 1 | 20 participants (Anticipated) | Interventional | 2017-08-22 | Recruiting | ||
| Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy [NCT03547375] | Phase 2 | 69 participants (Anticipated) | Interventional | 2018-06-01 | Not yet recruiting | ||
| An Open-label, Phase 2 Randomized Trial of Camrelizumab (SHR1210) Plus Apatinib Versus Paclitaxel and Cisplatin/Carboplatin Plus Bevacizumab as a First-line Therapy in Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer [NCT04974944] | Phase 2 | 172 participants (Anticipated) | Interventional | 2021-07-30 | Recruiting | ||
| Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy [NCT04968002] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2021-08-01 | Not yet recruiting | ||
| Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma in China: a Real-world Study [NCT04947956] | 1,000 participants (Anticipated) | Observational | 2021-09-01 | Not yet recruiting | |||
| A Single-arm, Multicenter, Open-labeled, Phase II Study on the Efficacy and Safety of Carelizumab Combined With Irinotecan and Apatinib in the Second-line Treatment of Locally Advanced Unresectable, Recurrent or Metastatic Adenocarcinoma of Stomach and Ga [NCT04934618] | Phase 2 | 85 participants (Anticipated) | Interventional | 2020-05-19 | Recruiting | ||
| An Exploratory Single-center, Open-label , Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer [NCT03199677] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed After First - Line Induction Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer: A Prospective, Open, Single Arm Clinical Study [NCT03190239] | Phase 2 | 20 participants (Anticipated) | Interventional | 2017-07-15 | Not yet recruiting | ||
| An Exploratory Study of Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases [NCT04832204] | Phase 2 | 20 participants (Anticipated) | Interventional | 2021-03-25 | Recruiting | ||
| Infusional FOLFOX Plus Camrelizumab and Apatinib Versus HAIC-FOLFOX Plus Camrelizumab and Apatinib for Hepatocellular Carcinoma of BCLC C Stage: A Multi-center Randomized Phase III Trial [NCT06172205] | Phase 3 | 192 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| Open-Label, Fixed-Sequence Study in Solid Tumor Subjects to Investigate the Pharmacokinetic Interaction Between Apatinib and Transporter Substrates Rosuvastatin and Metformin. [NCT04428086] | Phase 1 | 19 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
| a Phase II, Open-label, Single Arm Study of Sintilimab (an Anti-PD-1 Inhibitor) Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma [NCT04411706] | Phase 2 | 46 participants (Anticipated) | Interventional | 2020-06-21 | Recruiting | ||
| Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study [NCT04195828] | Phase 2 | 53 participants (Anticipated) | Interventional | 2020-06-18 | Active, not recruiting | ||
| A Single-arm Phase 2 Study of Apatinib (Anti-PD-1) Combined With Camrelizumab (Anti-VEGFR ) in Patients With Advanced Chordoma [NCT06140732] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-10-30 | Recruiting | ||
| Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Two-arm, Phase 2 Trial [NCT05277480] | Phase 2 | 78 participants (Anticipated) | Interventional | 2022-03-01 | Recruiting | ||
| Camrelizumab Combined With Apatinib for Recurrent Resistant Gestational Trophoblastic Neoplasia: a Phase 2, Single-arm, Prospective Study [NCT04047017] | Phase 2 | 20 participants (Actual) | Interventional | 2019-08-08 | Completed | ||
| A Randomized, Controlled, Open-label, Phase III Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer Based on SNF Molecular Classification [NCT05889871] | Phase 3 | 916 participants (Anticipated) | Interventional | 2023-06-01 | Not yet recruiting | ||
| A Phase 2 Study of Paclitaxel Plus Rivoceranib in Patients With GIST With a High P-glycoprotein Expression After Failure With at Least Imatinib, Sunitinib and Regorafenib [NCT05905887] | Phase 2 | 48 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| A Randomized, Open-Label, Multi-Center, Phase 2 Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablat [NCT05367687] | Phase 2 | 251 participants (Actual) | Interventional | 2022-09-01 | Active, not recruiting | ||
| A Phase II, Single-center, Randomized Study of Vinorelbine Plus Apatinib Versus Vinorelbine as Second-Line or Third-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer (NAN Trail) [NCT03254654] | Phase 2 | 66 participants (Actual) | Interventional | 2017-08-16 | Completed | ||
| Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas [NCT04253873] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-12-16 | Recruiting | ||
| A Randomized, Open-Label, Controlled, Multicenter Phase III Study of Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone Versus Platinum-based Chemotherapy for First-line Treatment in Subjects With PD-L1 Positive Relapsed or Advanced NSCLC [NCT04203485] | Phase 3 | 762 participants (Anticipated) | Interventional | 2020-06-15 | Not yet recruiting | ||
| MR and Histopathology Images Based Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas Using Artificial Intelligence [NCT04216550] | 600 participants (Anticipated) | Observational [Patient Registry] | 2018-01-01 | Recruiting | |||
| Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma [NCT04318730] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-06-12 | Recruiting | ||
| An Exploratory Study Evaluating the Safety and Efficacy of MASCT-I Combined With Apatinib Mesylate and/or Camrelizumab in the Treatment of Patients With Advanced Bone and Soft Tissue Sarcoma [NCT04074564] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2019-11-22 | Recruiting | ||
| Peripheral Circulating Blood Tumor Cells (CTC) Detection and CTC-based PD-L1 Antibody Immunofluorescence Detection to PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Second-line and Back-line Treatment of Advanced NSCLC, Soft Tissue Sarcoma, Uterine Can [NCT04239443] | Phase 2 | 120 participants (Anticipated) | Interventional | 2019-01-30 | Recruiting | ||
| One-arm Exploratory Study on the Efficacy and Safety of Apatinib Combined With SHR-1210 Injection (PD-1 Antibody) in the Treatment of Removable IB-IIIA Non-small Cell Lung Cancer [NCT04133337] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2019-11-01 | Not yet recruiting | ||
| A Pilot Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure [NCT02772029] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Not yet recruiting | ||
| Anti-PD-1 Antibody SHR-1210 Combined With Anti-angiogenesis Inhibitor Apatinib in Treatment of Extensive-stage Disease Small Cell Lung Cancer After Failure of First Line Standard Therapy [NCT03417895] | Phase 2 | 59 participants (Actual) | Interventional | 2018-04-20 | Completed | ||
| A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung [NCT03083041] | Phase 2 | 210 participants (Actual) | Interventional | 2017-03-22 | Completed | ||
| Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer：One-arm Exploratory Clinical Trial [NCT04067986] | Phase 1/Phase 2 | 62 participants (Anticipated) | Interventional | 2019-08-20 | Recruiting | ||
| A Single-Arm Phase II Trial of Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy [NCT04670913] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-06-28 | Recruiting | ||
| Combined Transarterial Chemoembolization, Tyrosine Kinase Inhibitor/ Anti-VEGF Antibody, and Anti-PD-1/ PD-L1 Antibody as Conversion Therapy for Advanced Hepatocellular Carcinoma: a Multicenters, Real-world, Ambispective Cohort Study [NCT05717738] | 300 participants (Anticipated) | Observational | 2022-01-20 | Recruiting | |||
| Combined Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitor/ Anti-VEGF Antibody, and Anti-PD-1/ PD-L1 Antibody as Conversion Therapy for Unresectable Hepatocellular Carcinoma [NCT05713994] | 300 participants (Anticipated) | Observational | 2020-05-19 | Recruiting | |||
| Fluzoparib Combined With Apatinib for Maintenance Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Phase II Single-arm, Open Label, Multicenter Trial [NCT06081595] | Phase 2 | 54 participants (Anticipated) | Interventional | 2023-10-30 | Not yet recruiting | ||
| A Single Arm Pilot Study of Programmed Cell Death Protein 1 Antibody (PD-1# SHR-1210 Combined With Apatinib Mesylate in Patients With Advanced-Stage Hepatocellular Carcinoma [NCT04014101] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-06-01 | Recruiting | ||
| Prospective, Randomized, Controlled, Multicenter, Phase III Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction [NCT03986385] | Phase 3 | 180 participants (Anticipated) | Interventional | 2019-06-01 | Recruiting | ||
| An Exploratory and Open Clinical Study of Apatinib Mesylate as First-line Treatment for Advanced Esophagus Cancer. [NCT03542422] | Phase 2 | 50 participants (Anticipated) | Interventional | 2018-06-30 | Not yet recruiting | ||
| Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach [NCT04863430] | Phase 2 | 41 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| Radiotherapy/Apatinib for Adjuvant Treatment of Hepatocellular Carcinoma Patients Accepted Curative Resection With Microvascular Invasion: a 2x2 Factorial Design Study [NCT03732105] | Phase 2 | 160 participants (Anticipated) | Interventional | 2018-11-01 | Not yet recruiting | ||
| Study of Apatinib in Metastatic Esophageal Cancer：A Open Label, Randomized Clinical Trial [NCT02683655] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-08-31 | Recruiting | ||
| Evaluating the Safety and Efficacy of Radioactive Iodine (RAI) Treatment of Metastatic and Advanced Differentiated Thyroid Cancers by Pretreatment With Apatinib for the Neoadjuvant Regimen [NCT04180007] | Phase 2 | 10 participants (Anticipated) | Interventional | 2019-04-10 | Recruiting | ||
| Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer: A Randomized, Parallel, Controlled Study [NCT02537171] | Phase 3 | 40 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma: a Multicenter, Prospective, Randomized Controlled Trial [NCT05789043] | Phase 3 | 140 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | ||
| Randomized, Open-label, Multi-center, Phase II Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma [NCT01192971] | Phase 2 | 121 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies [NCT02596256] | Phase 2 | 80 participants (Anticipated) | Interventional | 2016-04-30 | Active, not recruiting | ||
| A Phase II, Single-arm Study to Evaluate The Safety and Efficacy of Apatinib Combined With Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Albumin-bound Paclitaxel Plus Gemcitabine Regimen [NCT04101929] | Phase 2 | 126 participants (Anticipated) | Interventional | 2019-10-01 | Recruiting | ||
| Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study [NCT02702323] | Phase 2/Phase 3 | 40 participants (Anticipated) | Interventional | 2016-03-31 | Not yet recruiting | ||
| Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer: Randomized Control, Open, Multicenter Trial-2 (TAOS-3B-Trial-2) [NCT05699655] | Phase 2/Phase 3 | 130 participants (Anticipated) | Interventional | 2023-05-10 | Recruiting | ||
| PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Treatment Naive Advanced Gastric Cancer: A Phase II Study. [NCT04174339] | 20 participants (Anticipated) | Interventional | 2019-12-10 | Not yet recruiting | |||
| Camrelizumab Combined With Apatinib for Recurrent Platinum-resistant Ovarian Cancer: a Phase 2 Single-arm Prospective Study [NCT04068974] | Phase 2 | 28 participants (Anticipated) | Interventional | 2019-10-28 | Recruiting | ||
| A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs [NCT05556200] | Phase 2 | 58 participants (Anticipated) | Interventional | 2022-12-01 | Recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer [NCT03048877] | Phase 3 | 118 participants (Anticipated) | Interventional | 2016-12-31 | Active, not recruiting | ||
| A Phase 1, Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Bioequivalence of Four Formulations of Oral Rivoceranib Tablets in Healthy Subjects [NCT05287360] | Phase 1 | 60 participants (Actual) | Interventional | 2021-12-30 | Completed | ||
| Phase 1 Study of Apatinib as an Inhibitor of Angiogenesis [NCT00633490] | Phase 1 | 18 participants (Anticipated) | Interventional | 2007-07-31 | Recruiting | ||
| A Phase II Clinical Trial to Investigate Efficacy and Safety of Apatinib as a Single Agent in RET-fusion Gene Positive Non-small Cell Lung Cancer Who Failed to Previous Treatment. [NCT02540824] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| Apatinib as Second-line Treatment of Advanced Pancreatic Cancer, Phase II Clinical Study of Open Arm [NCT02726854] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer [NCT02697838] | Phase 2 | 20 participants (Actual) | Interventional | 2016-08-01 | Active, not recruiting | ||
| Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma [NCT04609293] | 30 participants (Anticipated) | Observational | 2020-10-20 | Not yet recruiting | |||
| Efficacy and Safety of Neoadjuvant Therapy With Sintilimab and Apatinib Combined Chemotherapy in Triple-negative Breast Cancer [NCT04722718] | Phase 2 | 34 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | ||
| A Phase 2 Clinical Trial of Neoadjuvant Camrelizumab Plus Apatinib and Temozolomide in High Risk Clinical Stage Ⅱ-Ⅲ Acral Melanoma [NCT05512481] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-09-13 | Recruiting | ||
| A Randomized Phase 2 Study to Evaluate Safety and Efficacy of the Combination of SHR-1210 With Capecitabine + Oxaliplatin or Apatinib as First-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [NCT03472365] | Phase 2 | 67 participants (Actual) | Interventional | 2018-04-02 | Completed | ||
| Efficacy and Safety of Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer [NCT04258644] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-03-01 | Not yet recruiting | ||
| Clinical Study of SHR-1210 Plus Apatinib in Patients With Advanced Mucosal Melanoma Whose Diseases Progress After Chemotherapy [NCT03986515] | Phase 2 | 40 participants (Anticipated) | Interventional | 2019-06-04 | Recruiting | ||
| An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib With Nivolumab in Patients With Unresectable or Metastatic Cancer [NCT03396211] | Phase 1 | 30 participants (Actual) | Interventional | 2017-12-22 | Completed | ||
| Randomized, Open, Positive Drug Control, Multicenter Clinical Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Squamous Cell Carcinoma With Chemotherapy in Patients Treated With Apatinib Mesylate [NCT03787251] | Phase 2 | 0 participants (Actual) | Interventional | 2019-01-01 | Withdrawn(stopped due to In China, apatinib has been approved as an indication drug for esophageal squamous cell carcinoma, which makes it very difficult for our clinical trial to enroll patients. We regret that we failed to implement the design as planned.) | ||
| Phase I/IIa, Single-Arm, Open Study of Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma [NCT02848794] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| Phase II Study of Apatinib Combined With Oral Vinorelbine in Pretreated Metastatic HER2 Negative Breast Cancer [NCT02768415] | Phase 2 | 40 participants (Actual) | Interventional | 2016-06-30 | Active, not recruiting | ||
| Randomized, Controlled, Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of RC48-ADC for the Treatment of Locally Advanced or Metastatic Gastric Cancer With HER2-overexpression [NCT04714190] | Phase 3 | 351 participants (Anticipated) | Interventional | 2021-03-24 | Recruiting | ||
| A Pilot Study of Second-line Treatment With Apatinib After Trans Arterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma Patients [NCT02727309] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy [NCT02776527] | Phase 4 | 40 participants (Anticipated) | Interventional | 2016-04-30 | Recruiting | ||
| Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study. [NCT02704767] | Phase 2 | 60 participants (Anticipated) | Interventional | 2016-06-30 | Not yet recruiting | ||
| Apatinib Versus Bevacizumab in Combination With Second-line FOLFIRI in Patients With Metastatic Colorectal Cancer That Progressed During or After First-line Bevacizumab Plus an Oxaliplatin-based Regimen: A Randomised Phase 2 Trial [NCT03271255] | Phase 2 | 80 participants (Anticipated) | Interventional | 2018-05-23 | Recruiting | ||
| A Multicenter, Phase 3 Clinical Trial of Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma [NCT05854849] | Phase 3 | 244 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| PD-1 Antibody Combined With Apatinib Mesylate as 2+ Line Treatment of Serum AFP-elevated Gastric Adenocarcinoma: an Open-label, Single-arm, Multicenter Phase II Study [NCT04006821] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-07-25 | Recruiting | ||
| A Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Apatinib Mesylate on CYP2C8 Substrate Repaglinide or CYP2B6 Substrate in Advanced Solid Tumor Subjects [NCT04457180] | Phase 1 | 18 participants (Actual) | Interventional | 2020-11-16 | Completed | ||
| Exploratory Clinical Study of the Combination of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer [NCT02942329] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| A Single Group, Open Label, Multi-center Clinical Study of Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of Hepatocellular Cancer Before Liver Transplant [NCT04035876] | Phase 1/Phase 2 | 120 participants (Anticipated) | Interventional | 2019-07-16 | Recruiting | ||
| AMELIE: A Phase 3 Randomized, Open-label, Multicenter Trial of Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant or Refractory Ovarian Cancer [NCT04000295] | Phase 3 | 280 participants (Anticipated) | Interventional | 2019-08-16 | Recruiting | ||
| SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy：a Prospective Exploratory Study [NCT04878107] | Phase 2 | 88 participants (Anticipated) | Interventional | 2022-03-15 | Recruiting | ||
| Phase II Study of Apatinib Mesylate Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck [NCT02775370] | Phase 2 | 68 participants (Actual) | Interventional | 2016-05-31 | Active, not recruiting | ||
| A Randomized Controlled Clinical Trial of Temozolomide Plus Apatinib in Newly Diagnosed High-grade Glioma [NCT03741244] | Phase 2 | 211 participants (Anticipated) | Interventional | 2019-05-06 | Recruiting | ||
| Single-arm Exploratory Clinical Study on the Second-line Treatment of Advanced Gastric Cancer With Apatinib Mesylate Plus Capecitabine [NCT03531931] | 20 participants (Anticipated) | Observational | 2018-05-31 | Not yet recruiting | |||
| An Exploratory Study to Evaluate Radiotherapy Combined With Irinotecan Liposome and Apatinib Followed by PD-1 Antibody and Apatinib for the Treatment of Advanced Solid Tumors That Failed Standard Treatments [NCT04569916] | Phase 2 | 30 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Intravenous mFOLFOX7 Plus Camrelizumab and Apatinib for CNLC Stage III Hepatocellular Carcinoma [NCT05412589] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-06-10 | Recruiting | ||
| A Exploratory Clinical Trial Study on Apatinib in the Treatment of Metastatic Colorectal Cancer Who Have Progressed After Standard Second Line Therapy [NCT03403452] | Phase 2 | 33 participants (Anticipated) | Interventional | 2018-01-01 | Recruiting | ||
| The Efficacy and Safety of Anti-PD-1 Antibody Camrelizumab Combined With Apatinib for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study [NCT04612894] | Phase 2 | 31 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Apatinib Mesylate Combined With Albumin Binds Paclitaxel and Carboplatin or Cisplatinum as First-line Treatment for Stage II-IV Epithelial Ovarian Cancer Followed by Apatinib Maintenance Therapy:a Single-arm,Exploratory Clinical Study [NCT04590625] | Phase 2 | 58 participants (Anticipated) | Interventional | 2020-10-31 | Recruiting | ||
| A Study to Evaluate the Safety and Efficiency of Using the Neoadjuvant Therapy With Carilizumab and Apatinib in Patients With Recurrent High-Grade Glioma ：A Prospective, Randomized Study [NCT04588987] | Phase 2 | 60 participants (Anticipated) | Interventional | 2020-10-31 | Recruiting | ||
| Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal Cancer [NCT04073615] | Phase 1/Phase 2 | 29 participants (Actual) | Interventional | 2019-11-18 | Completed | ||
| A Phase II, Single-arm, Open-labeled Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC [NCT03463876] | Phase 2 | 190 participants (Actual) | Interventional | 2018-02-05 | Completed | ||
| The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer [NCT03007446] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| A Phase Ib/II Trial Evaluating the Efficacy and Safety of Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma [NCT05924997] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2023-07-01 | Not yet recruiting | ||
| Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer： a Single-arm, Multicenter， Prospective Phase II Study [NCT04572542] | Phase 1/Phase 2 | 46 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | ||
| Efficacy and Safety of Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: a Single-center, Single-arm, Phase 2 Trail [NCT04547088] | Phase 2 | 27 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Effect of Itraconazole on the Pharmacokinetics of Apatinib in Chinese Healthy Volunteers [NCT02836171] | Phase 1 | 20 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients [NCT02774200] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-05-31 | Not yet recruiting | ||
| Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: Multi-center, Single-arm, Phase II Clinical Study. [NCT05027386] | Phase 2 | 62 participants (Anticipated) | Interventional | 2021-08-26 | Recruiting | ||
| A Single-arm, Non-randomized, Single-center Study to Evaluate Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer [NCT04560127] | Phase 2 | 20 participants (Anticipated) | Interventional | 2020-09-23 | Recruiting | ||
| Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center of China [NCT06145308] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-12-01 | Recruiting | ||
| A Randomized Phase 2/3 Study of Apatinib as Third Line Treatment in Patients With Metastatic Gastric Carcinoma [NCT00970138] | Phase 2/Phase 3 | 141 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal Cancer With Previous Standard Treatment Failure ：an Exploratory, Single-arm, Open-label, Phase II Trial [NCT05225844] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| Apatinib and Irinotecan Combination as Second-line Treatment in Esophageal Squamous Cell Carcinoma: a Phase I Dose Escalation Study [NCT02645864] | Phase 1 | 12 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| The Efficacy and Safety of Apatinib Combined With Etoposide in Advanced Non-small Cell Lung Cancer Patients Failed to Previous at Least 2rd Line Treatments [NCT02733107] | Phase 2 | 25 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | ||
| A Prospective Multicenter Phase II Clinical Trial of Apatinib Mesylate Tablets Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma [NCT04350190] | Phase 2 | 25 participants (Actual) | Interventional | 2021-01-14 | Completed | ||
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of Fluzoparib±Apatinib for Maintenance Treatment in Patients With Advanced Ovarian Cancer Who Have Achieved Effective Response After [NCT04229615] | Phase 3 | 690 participants (Actual) | Interventional | 2020-06-02 | Active, not recruiting | ||
| A Phase II Study of Apatinib In Combination With Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer [NCT02867956] | Phase 2 | 35 participants (Anticipated) | Interventional | 2016-08-10 | Completed | ||
| A Phase I, Open-label, Dose-escalation Study of Apatinib in Combination With Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type Epidermal Growth Factor Receptor (EGFR) [NCT02691871] | Phase 1 | 20 participants (Anticipated) | Interventional | 2016-02-29 | Not yet recruiting | ||
| A Multicenter, Randomized, Open, Phase 2 Trial of SHR-1210 Plus Apatinib Versus Doxorubicin(ADM) Plus Ifosfamide（IFO）in Patients With Soft Tissue Sarcoma [NCT03711279] | Phase 2 | 99 participants (Actual) | Interventional | 2018-11-22 | Terminated(stopped due to Sponsor R & D Strategy Adjustment) | ||
| An Exploratory Study on the Safety and Efficacy of Cryoablation Combined With Camrelizumab and Apatinib in the Treatment of Multiprimary Lung Cancer With Non-known Driving Genes [NCT04201990] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2019-12-31 | Not yet recruiting | ||
| Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer [NCT04182724] | Phase 1/Phase 2 | 57 participants (Anticipated) | Interventional | 2019-11-12 | Recruiting | ||
| A Single Arm, Observational Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment With PD-1 Monoclonal Antibody Plus Apatinib and SBRT in HCC With PVTT [NCT04165174] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-12-31 | Recruiting | ||
| A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients [NCT02829385] | Phase 2 | 53 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Prospective, Randomized, Single-center Phase II Clinical Study of Camrelizumab Combined With Apatinib Versus Apaitnib Alone in the Third-line Treatment of Metastatic Gastric Cancer [NCT05342389] | Phase 2 | 68 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| A Prospective, Non-randomized, Multicenter, Phase II Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Unresectable Recurrent or Metastatic Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma [NCT04609176] | Phase 2 | 64 participants (Anticipated) | Interventional | 2020-11-18 | Recruiting | ||
| Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer -- Multicenter, Open, One Arm Exploratory Study [NCT03255811] | 40 participants (Anticipated) | Interventional | 2017-03-25 | Enrolling by invitation | |||
| SHR-1210, a Novel Anti-pd-1 Antibody, in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: a Single-arm, Open Label, Multi-center, Phase II Study [NCT03816553] | Phase 2 | 45 participants (Actual) | Interventional | 2019-01-19 | Completed | ||
| Effect of Rifampicin on the Pharmacokinetics of Apatinib in Chinese Healthy Volunteers [NCT02836821] | Phase 1 | 20 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy [NCT02711007] | Phase 2/Phase 3 | 37 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| A Randomized, Controlled, Multicenter Clinical Study of Camrelizumab in Combination With Apatinib Mesylate and Chemotherapy Versus Camrelizumab Plus Chemotherapy in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma [NCT05738434] | Phase 2 | 188 participants (Anticipated) | Interventional | 2023-03-02 | Recruiting | ||
| A Randomized Controlled Study of Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide and Cisplatin Chemotherapy [NCT02875457] | Phase 3 | 100 participants (Anticipated) | Interventional | 2016-09-30 | Not yet recruiting | ||
| A Phase II, Open-label, Single Arm, Investigator-initiated Trail of An Anti-PD-1 Inhibitor SHR-1210 in Combination With Apatinib in the Perioperative Treatment of Hepatocellular Carcinoma [NCT04297202] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-12-01 | Recruiting | ||
| A Single -Arm, Open-label, Multicenter Phase II Study of Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) [NCT04683198] | Phase 2 | 69 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer [NCT03086785] | Phase 2 | 120 participants (Anticipated) | Interventional | 2016-11-24 | Recruiting | ||
| Surgical Conversion of Candonilimab (AK104) Combined With Paclitaxel, S-1 and Apatinib for Unresectable Advanced Gastric(G)/Gastroesophageal Junction(GEJ) Cancer [NCT05853172] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-03-21 | Recruiting | ||
| Apatinib in Combination With SBRT Treatment for Symptomatic Metastatic [NCT02998242] | 40 participants (Anticipated) | Interventional | 2016-05-10 | Completed | |||
| A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase II Study of Apatinib as Third Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer [NCT01270386] | Phase 2 | 136 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [NCT03276156] | Phase 1 | 12 participants (Anticipated) | Interventional | 2016-02-23 | Recruiting | ||
| Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Phase II, Prospective, Single-arm, Multicenter Trial [NCT03274011] | Phase 2 | 40 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| A Exploratory Study of Apatinib in Combination With S1 in Patients With Advanced Gastric Evaluating the Efficacy and Safety [NCT03271073] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-02-01 | Recruiting | ||
| PhaseⅡSingle-center, Open-label, Exploratory Clinical Study of Apatinib in Combination With S1 for the Patients With Advanced Non-squamous Head and Neck Cancer [NCT02943252] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| A Phase II Randomized Trial of Efficacy and Safety of Particle Therapy With or Without Apatinib as Induction Therapy for Treatment of Head and Neck Adenoid Cystic Carcinoma [NCT02942693] | Phase 2 | 50 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| A PhaseⅠStudy of Apatinib Mesylate (YN968D1) 1,000mg in Patients With Unresectable Locally Advanced or Metastatic Gastric Cancer Failed to Standard Therapy [NCT02711969] | Phase 1 | 6 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
| Systemic Chemotherapy Based on Oxaliplatin and 5-fluorouracil, Apatinib Plus Sintilimab for Metastasis ICC: a Single Arm Prospective Study [NCT04682249] | Phase 2 | 0 participants (Actual) | Interventional | 2020-12-01 | Withdrawn(stopped due to no patients enrolled) | ||
| A Single-arm Study to Evaluate the Safety and Efficacy of Recombinant Oncolytic Virus M1 (M1-c6v1) Combined With Anti-PD-1 Antibody SHR-1210 and Apatinib for Treatment of Patients With Advanced / Metastatic Hepatocellular Carcinoma [NCT04665362] | Phase 1 | 10 participants (Anticipated) | Interventional | 2021-01-25 | Not yet recruiting | ||
| A Non-randomized Phase II Study of Apatinib and Tegafur Gimeracil Oteracil Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck [NCT03267121] | Phase 2 | 38 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Single-Arm,Single-Center, Phase Ib/II Clinical Study of Fluzoparib (SHR-3162) Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（SCLC） [NCT04659785] | Phase 1/Phase 2 | 53 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | ||
| Cryoablation Combined With Camrelizumab and Apatinib [NCT04724226] | Phase 2 | 34 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | ||
| Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC): A Prospective Clinical Study [NCT04642664] | Phase 2 | 22 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer(APPROVE): a Randomized, Controlled, Open-label, Phase 2 Trial [NCT04348032] | Phase 2 | 152 participants (Actual) | Interventional | 2018-03-22 | Active, not recruiting | ||
| Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer [NCT03587129] | Phase 2 | 1 participants (Actual) | Interventional | 2018-07-10 | Terminated(stopped due to No patient enter this study.) | ||
| Apatinib Mesylate Combined With Albumin-bound Paclitaxel for Second-line Treatment of Advanced Triple Negative Breast Cancer:a Single-arm,Exploratory Clinical Study [NCT05019690] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2021-10-01 | Not yet recruiting | ||
| Camrelizumab Combined With Apatinib and Gemcitabine Plus Cisplatin as First-line Therapy for Patients With Inoperable/Metastatic Biliary Tract Cancer (BTC): An Open-label, Single-arm, Single-center, Phase Ib/II Clinical Study [NCT05742750] | Phase 1/Phase 2 | 48 participants (Anticipated) | Interventional | 2023-03-01 | Not yet recruiting | ||
| A Randomized Controlled, Open-label, Multicenter Phase III Clinical Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib and Camreli [NCT05313282] | Phase 3 | 140 participants (Anticipated) | Interventional | 2022-06-15 | Recruiting | ||
| A Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE) [NCT03407976] | Phase 1 | 5 participants (Actual) | Interventional | 2018-06-19 | Terminated(stopped due to Funding source withdrew financial support prior to start of Phase II portion of study) | ||
| The Multi-center, Randomized and Controlled Phase II Trail of Apatinib Mesylate Tablets Combined With PD-1 Antibody SHR-1210 for Adjuvant Treatment of Patients With High Recurrence Risk After Radical Operation of Hepatocellular Carcinoma [NCT03839550] | Phase 2 | 200 participants (Anticipated) | Interventional | 2019-02-15 | Not yet recruiting | ||
| A Phase II Clinical Study Evaluating the Safety and Efficacy of Camrelizumab Combined With Chemotherapy and Apatinib as First Line Treatment in Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas（EP-NEC） [NCT05142865] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-01-14 | Not yet recruiting | ||
| A Single-arm Prospective Clinical Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin for the Neoadjuvant Treatment of Biliary Tract Malignancies [NCT06181032] | Phase 1 | 35 participants (Anticipated) | Interventional | 2023-12-23 | Not yet recruiting | ||
| A Phase 2 Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic Adenoid Cystic Carcinoma of All Anatomic Sites of Origin [NCT04119453] | Phase 2 | 80 participants (Actual) | Interventional | 2020-03-04 | Completed | ||
| A Randomized Trial of Comparison of MAPI+Camrelizumbab Verus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcomaies : an Open-label, Exploratory Study [NCT04351308] | Phase 2 | 60 participants (Anticipated) | Interventional | 2020-05-01 | Recruiting | ||
| Apatinib Plus S-1 for Advanced Gastric Cancer Refractory to Oxaliplatin Plus Capecitabine Combination Therapy: A Single-arm, Phase-2, Home-based Trial [NCT04338438] | Phase 2 | 37 participants (Actual) | Interventional | 2015-05-01 | Completed | ||
| Camrelizumab Combined Apatinib in Patients With Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors: A Single-Arm, Open-Label, Phase II Study. [NCT04826406] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-02-03 | Recruiting | ||
| An Efficacy and Safety Study of Camrelizumab in Combination With Apatinib Mesylate and Oxaliplatin for Neoadjuvant Therapy in Patients With Potentially Resectable Hepatocellular Carcinoma. [NCT04850040] | Phase 2 | 15 participants (Anticipated) | Interventional | 2021-05-06 | Not yet recruiting | ||
| A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Fluzoparib±Apatinib Versus Physicians Choice Chemotherapy in the Treatment of HER2-negative Metastatic Breast Cancer Patients With Germline BRCA1/2 Mu [NCT04296370] | Phase 3 | 474 participants (Anticipated) | Interventional | 2020-07-13 | Recruiting | ||
| Camrelizumab, Apatinib Plus Hepatic Arterial Infusion Chemotherapy Versus Camrelizumab and Apatinib for Hepatocellular Carcinoma With Portal Vein Invasion: a Randomized, Open-label, Multicentre Trial [NCT05198609] | Phase 3 | 214 participants (Anticipated) | Interventional | 2022-01-17 | Recruiting | ||
| A Single-center, Prospective, Single-arm Phase II Clinical Study on the Efficacy and Safety of TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer [NCT05550025] | Phase 2 | 26 participants (Anticipated) | Interventional | 2021-12-17 | Recruiting | ||
| A Randomized,Parallel Controlled,Multicentre,Phase II Study of Apatinib Plus POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) Versus POF in Patients With Advanced/Metastatic Bastric Cancer [NCT04121039] | Phase 2 | 116 participants (Anticipated) | Interventional | 2019-12-31 | Not yet recruiting | ||
| A Randomized, Controlled Phase II Clinical Trial of Apatinib in Combination With EGFR-TKI Versus EGFR-TKI for Non-squamous, Non-small Cell Lung Cancer(NSCLC) With T790M-negative After the Failure of EGFR-TKI Therapy [NCT03389256] | Phase 2 | 144 participants (Anticipated) | Interventional | 2018-12-30 | Not yet recruiting | ||
| A Random, Open, Dose Finding and Pharmacokinetics/Pharmacodynamics(PK/PD) Phase II Study of Apatinib Tablets in the Treatment of Advanced Colorectal Cancer [NCT01531777] | Phase 2 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Single-arm, Exploratory Clinical Study of Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Apatinib and Camrelizumab in the Treatment of Unresectable Macrotrabecular-massive Hepatocellular Carcinoma [NCT05839197] | Phase 2 | 38 participants (Anticipated) | Interventional | 2023-05-05 | Recruiting | ||
| SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Technically Resectable Hepatocellular Carcinoma [NCT04930315] | Phase 2 | 78 participants (Anticipated) | Interventional | 2021-09-15 | Recruiting | ||
| A Multicenter, Open, Single Arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma [NCT05265793] | Phase 2 | 45 participants (Anticipated) | Interventional | 2021-11-21 | Recruiting | ||
| A Phase I/II Clinical Study to Compare Postoperative Chemotherapy of Oxaliplatin With Capecitabine（XELOX）Combined With APATINIB as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection [NCT03599778] | Phase 1/Phase 2 | 52 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| A Study on the Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer [NCT04345783] | Phase 2 | 30 participants (Actual) | Interventional | 2018-01-01 | Active, not recruiting | ||
| A Phase II Clinical Trial Study on Apatinib and Chemotherapy Sequential Treatment With Advanced Metastatic Cervical Cancer [NCT03029013] | 30 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | |||
| A Non-randomized, Open-label, Prospective, Single-center Study of Apatinib Mesylate Tablet as Third-line and Later Therapy in Patients With Small Cell Cancer（SCLC） [NCT02995187] | Phase 2 | 25 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Apatinib in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: A Prospective, Single-Center, Phase II Study [NCT05290116] | Phase 2 | 17 participants (Anticipated) | Interventional | 2022-07-21 | Recruiting | ||
| A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver Cancer（PLC）or Biliary Tract Carcinoma (BTC) [NCT03092895] | Phase 2 | 157 participants (Actual) | Interventional | 2017-04-27 | Completed | ||
| Clinical Efficacy of Carrelizumab, Apatinib Mesylate, Albumin Paclitaxel Combined With Oxaliplatin and S-1 in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes--A Prospective, Multi-center, Randomized Controlled Study [NCT05524974] | Phase 2 | 203 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| A Phase II Clinical Study of Neoadjuvant Therapy for Resectable Locally Advanced Gastric Cancer With PD-1 Antibody or in Combination With Apatinib ± S1±Oxaliplatin [NCT03878472] | Phase 2 | 30 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| A Phase 2 Randomized, Open-label, Multicenter Trial of Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant or Refractory Ovarian Cancer [NCT04383977] | Phase 2 | 54 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | ||
| Antiangiogenic Therapy or Chemotherapy Combined With PD-1 Inhibitor Versus Standard Chemotherapy for PD-1 Inhibitor Refractory R/M NPC [NCT05549466] | Phase 2 | 84 participants (Anticipated) | Interventional | 2022-10-08 | Recruiting | ||
| Clinical Study of Apatinib in the Treatment of Recurrent Atypical/Malignant Meningioma in Adults [NCT04501705] | 29 participants (Anticipated) | Interventional | 2020-08-18 | Recruiting | |||
| Efficacy and Safety of Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: a Single-center, Single-arm, Phase 2 Trail [NCT04548271] | Phase 2 | 25 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Camrelizumab Combined With Apatinib and Capecitabine for Patients With Advanced Unresectable Biliary Tract Cancer: a Phase 2, Single-arm, Prospective Study. [NCT04720131] | Phase 2 | 39 participants (Anticipated) | Interventional | 2021-02-01 | Not yet recruiting | ||
| A Single-arm, Multicenter Phase II Clinical Study of Camrelizumab Combined With Apatinib and Chemotherapy Followed by Radiotherapy in the Perioperative Treatment of Gastroesophageal Junction Adenocarcinoma [NCT06163729] | Phase 2 | 68 participants (Anticipated) | Interventional | 2022-08-25 | Recruiting | ||
| A Multi-institutional, Open-label, Single Arm Study of Apatinib in Non-triple-negative Metastatic Breast Cancer [NCT01653561] | Phase 2 | 20 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized, Open-Label, Controlled, International Multi-Center Phase III Clinical Study of Camrelizumab Combined With Rivoceranib (Apatinib) Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Hepatocellular Carcinoma (HCC) Wh [NCT04985136] | Phase 3 | 1 participants (Actual) | Interventional | 2021-09-26 | Terminated(stopped due to Sponsor R & D Strategy Adjustment) | ||
| An Open, Multicenter, Phase Ib/II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection in Patients With Advanced Gastric/ Gastroesophageal Junction Adenocarcinoma and Pancreatic Cancer [NCT04581473] | Phase 1/Phase 2 | 192 participants (Anticipated) | Interventional | 2020-10-23 | Recruiting | ||
| A Exploratory Study of Apatinib Adjuvant Therapy for Hepatocellular Carcinoma With Portal Vein Invasion Who Underwent Radical Resection [NCT03261791] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-07-20 | Recruiting | ||
| A Phase II Clinical Study Evaluating The Efficacy and Safety of KN046 in Combination With Regorafenib or Apatinib for Microsatellite Instability-High Digestive System Cancers Resistant to PD-1/PD-L1 Blockade [NCT06099821] | Phase 2 | 39 participants (Anticipated) | Interventional | 2023-10-25 | Recruiting | ||
| A Randomized, Double Blinded, Placebo Controlled Multicenter Phase III Study of Apatinib Mesylate Tablets in the Treatment of Advanced or Metastatic Gastric Cancer [NCT01512745] | Phase 3 | 267 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients [NCT04782622] | 60 participants (Anticipated) | Observational | 2021-03-01 | Recruiting | |||
| The Clinical Study of Apatinib for Patients With Advanced Non-squamous Head and Neck Cancer [NCT02989259] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma Progressed After Immune Checkpoint Inhibitors:a Single-arm,Open-label Prospective Trial [NCT04948125] | Phase 2 | 20 participants (Anticipated) | Interventional | 2021-04-28 | Recruiting | ||
| Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma [NCT04479527] | Phase 2 | 34 participants (Anticipated) | Interventional | 2021-04-30 | Not yet recruiting | ||
| A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC (Artemis) [NCT04803539] | Phase 2/Phase 3 | 260 participants (Anticipated) | Interventional | 2021-04-01 | Recruiting | ||
| A Clincal Trial of Apatinib Mesylate and Etoposide(VP-16) as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy [NCT03135977] | Phase 2 | 36 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma: a Prospective, Multi-center Stud [NCT05660213] | Phase 4 | 600 participants (Anticipated) | Interventional | 2024-01-30 | Not yet recruiting | ||
| TACE Combined With Camrelizumab and Apatinib Versus TACE in Intermediate and Advanced Hepatocelluar Carcinoma: a Randomized, Open-label, Multi-center Clinical Trials [NCT04559607] | 188 participants (Actual) | Interventional | 2020-09-11 | Active, not recruiting | |||
| A Single Arm, Open and Fixed Sequence Study to Investigate the Pharmacokinetic Effects of Apatinib Mesylate on Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects [NCT04322552] | Phase 1 | 18 participants (Actual) | Interventional | 2020-03-12 | Completed | ||
| A Phase 2 Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in the Treatment of Relapsed Ovarian Cancer Patients [NCT04517357] | Phase 2 | 142 participants (Anticipated) | Interventional | 2020-10-16 | Recruiting | ||
| A Single-center, Single-arm Exploratory Clinical Study of Apatinib Mesylate Tablets Combined With S-1 in the Treatment of Second-line or More Advanced Small Cell Lung Cancer [NCT04128800] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-10-31 | Recruiting | ||
| A Umbrella Study in Relapsed/Refractory Peripheral T-cell Lymphoma Guided by Molecular Subtypes [NCT05559008] | Phase 1/Phase 2 | 116 participants (Anticipated) | Interventional | 2022-09-30 | Recruiting | ||
| A Phase II Multicenter, Randomized, Double-blind Study of Apatinib Combined With Paclitaxol Versus Placebo With Paclitaxol as Second Line Therapy for Advanced Gastric / Esophagogastric Junction Adenocarcinoma With Peritoneal Metastasis. [NCT03144843] | Phase 2 | 110 participants (Anticipated) | Interventional | 2017-01-13 | Recruiting | ||
| Phase 1 Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer [NCT03132025] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-04-30 | Not yet recruiting | ||
| A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib [NCT03475589] | Phase 4 | 217 participants (Anticipated) | Interventional | 2018-02-26 | Recruiting | ||
| Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma：An Open-Label, Single-center, Single-arm Study [NCT03383237] | Phase 2 | 20 participants (Anticipated) | Interventional | 2017-11-29 | Recruiting | ||
| The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients [NCT06102707] | 50 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | |||
| Anti-PD-1 Antibody SHR-1210 (Camrelizumab) Combined With Apatinib Mesylate in the Treatment of Unresectable Sarcoma With Chemotherapy Failure: an Open, Non-randomized Phase II Clinical Study [NCT04126993] | Phase 2 | 80 participants (Anticipated) | Interventional | 2019-06-01 | Recruiting | ||
| Single-center, Open, Non-randomized, Phase II Prospective Study of Apatinib Combined With Chemotherapy in the Treatment of Unresectable Soft Tissue Sarcoma [NCT04126811] | Phase 2 | 120 participants (Anticipated) | Interventional | 2019-06-01 | Recruiting | ||
| Drug-eluting Beads Transarterial Chemoembolization Combined With Apatinib and PD-1 Antibody for the Treatment of Intrahepatic Cholangiocarcinoma That Has Progressed After Standard First-line Chemotherapy [NCT04834674] | Phase 2 | 20 participants (Anticipated) | Interventional | 2021-05-01 | Not yet recruiting | ||
| Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer [NCT02980809] | Phase 2 | 60 participants (Anticipated) | Interventional | 2017-03-31 | Not yet recruiting | ||
| A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction [NCT03349866] | Phase 2 | 48 participants (Anticipated) | Interventional | 2017-11-30 | Recruiting | ||
| Effectiveness and Safety of Apatinib for the Patients With Advanced Soft Tissue Sarcoma [NCT03064243] | Phase 2 | 53 participants (Anticipated) | Interventional | 2017-03-01 | Not yet recruiting | ||
| Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Had Failed Prior Platinum Based Chemotherapy [NCT03213587] | Phase 2 | 51 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| A Prospective Study of the Efficacy and Safety of Apatinib Monotherapy as First-Line Treatment in Elderly Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [NCT03219593] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-09-07 | Recruiting | ||
| A Randomized, Parallel Control, Exploratory Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in Subjects With Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction [NCT03030937] | Phase 2 | 74 participants (Anticipated) | Interventional | 2017-02-01 | Not yet recruiting | ||
| A Single-arm, Open-label, Phase Ⅱ Clinical Trial of Anti-PD-1 Antibody SHR-1210 Combined With Apatinib Mesylate as a Second-line Treatment for Advanced Esophageal Squamous Cell Carcinoma [NCT03736863] | Phase 2 | 85 participants (Anticipated) | Interventional | 2019-12-05 | Recruiting | ||
| A Phase III, Randomized, Open-Label, Multi-center Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) or TACE Alone in Patients With Incurable Hepatocellular Carcinoma [NCT05320692] | Phase 3 | 360 participants (Anticipated) | Interventional | 2022-08-09 | Recruiting | ||
| A Phase I/IIa Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer [NCT03707028] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2018-10-01 | Terminated(stopped due to Terminated after completion of Part 1 due to a change in research plan.) | ||
| Fluzoparib Combined With Apatinib Versus Fluzoparib for Maintenance Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Randomized, Open Label, Controlled, Multicenter Trial [NCT05479487] | Phase 2 | 132 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | ||
| A Multicenter Phase II Trial of Pemetrexed Plus Carboplatin With or Without Apatinib in Patients With Advanced Non-small Cell Lung Cancer Without EGFR Mutation, ALK Gene Rearrangement, and ROS1 Gene Rearrangement [NCT03164694] | Phase 2 | 128 participants (Anticipated) | Interventional | 2017-05-20 | Recruiting | ||
| Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb Hepatocellular Carcinoma [NCT05062837] | Phase 2/Phase 3 | 62 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced Gastrointestinal Stromal Tumors: a Randomized, Open, Controlled, Single-center Clinical Study [NCT05751733] | 258 participants (Anticipated) | Interventional | 2023-02-01 | Recruiting | |||
| A Multi-center, Non-randomized, Open-label, Parallel Study to Evaluate the Pharmacokinetics of Apatinib Mesylate in Subjects With Impaired Renal Function and Healthy Subjects [NCT04414852] | Phase 1 | 24 participants (Anticipated) | Interventional | 2020-06-05 | Not yet recruiting | ||
| A Single-cencer,Phase II Study of Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma [NCT04331093] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Apatinib Combined With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Used for the Advanced Slow-progressed Non Small Cell Lung Cancer Patients With EGFR-TKI Resistance [NCT03428022] | Phase 3 | 54 participants (Anticipated) | Interventional | 2017-12-01 | Recruiting | ||
| A Phase II Study of Apatinib Treatment for Advanced Biliary Tract Carcinoma After Failure of the First-line Chemotherapy [NCT03427242] | Phase 2 | 55 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | ||
| Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia: a Cohort, Open-label, Phase 2 Trial [NCT05139095] | Phase 2 | 73 participants (Anticipated) | Interventional | 2022-01-27 | Recruiting | ||
| A Single-arm Exploratory Clinical Study of Conversion Treatment of Hepatic Arterial Infusion Chemotherapy Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma [NCT05099848] | Phase 2 | 21 participants (Actual) | Interventional | 2021-03-17 | Active, not recruiting | ||
| Gefitinib Versus Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance：A Randomized, Multicentre, Phase II Study [NCT03267654] | Phase 2 | 100 participants (Anticipated) | Interventional | 2017-10-12 | Recruiting | ||
| The Biomarkers Identification for Apatinib and Bevacizumab in the Second-line Therapy for Colorectal Cancer: A Randomised Controlled Trial [NCT03743428] | 40 participants (Anticipated) | Interventional | 2020-10-22 | Suspended(stopped due to Too slow speed for recruiting.) | |||
| A Study of Camrelizumab (SHR-1210) Combined With Apatinib Versus Paclitaxel or Irinotecan in Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma Progressed After First-line Chemotherapy [NCT04342910] | Phase 3 | 550 participants (Anticipated) | Interventional | 2020-09-21 | Recruiting | ||
| Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer ：Single Arm Exploratory Study [NCT02974933] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| Efficacy and Safety of Apatinib Mesylate in Recurrent/Metastatic Esophageal Squamous Cell Carcinoma After the Failure of Conventional Treatment: a Phase II Clinical Trial [NCT02976896] | Phase 2 | 43 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Camrelizumab Plus Apatinib Combined With GEMOX (Gemcitabine and Oxaliplatin ) in the Perioperative Treatment of Locally Advanced Biliary Tract Malignancies: A Prospective, Multicenter, Phase Ⅱ Study [NCT05451290] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| A Prospective, Multicenter, Randomized Controlled Study of Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy [NCT05029453] | Phase 4 | 60 participants (Anticipated) | Interventional | 2021-08-26 | Not yet recruiting | ||
| A Randomized, Open-Label, Multi-Center, Phase Ⅲ Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation [NCT04639180] | Phase 3 | 687 participants (Actual) | Interventional | 2021-04-01 | Active, not recruiting | ||
| Multicenter Phase II Study of Apatinib in Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis [NCT02878057] | Phase 2 | 30 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled, Phase III Trial of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR) [NCT02332512] | Phase 3 | 417 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib and Paclitaxel in the 2nd Line Treatment of Patients With Recurrent or Metastatic Gastric Cancer [NCT03026881] | Phase 1 | 24 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| A Phase I Study to Characterize the Tolerance, Safety, Pharmacokinetics/Pharmacodynamics and Effect of PD-1 Inhibitor SHR-1210 in Combination With IDO Inhibitor SHR9146 and With/Without Apatinib in Patients With Advanced Solid Tumors (PIANO) [NCT03491631] | Phase 1 | 23 participants (Actual) | Interventional | 2018-11-20 | Active, not recruiting | ||
| Anti-PD-1 Antibody SHR-1210 Combined With Apatinib Versus SHR-1210 in the Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma：A Multicentre，Randomized， Open Label，Phase 3 Study [NCT05049681] | Phase 3 | 234 participants (Anticipated) | Interventional | 2021-12-05 | Not yet recruiting | ||
| Apatinib With Postoperative Adjuvant Chemotherapy for Operable Colorectal Cancer [NCT03228043] | 0 participants (Actual) | Interventional | 2020-03-01 | Withdrawn(stopped due to It's not possible to complete in our hospital.) | |||
| Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment [NCT03224221] | Phase 2 | 189 participants (Anticipated) | Interventional | 2017-03-23 | Recruiting | ||
| A Phase II Study of Gemcitabine-docetaxel Chemotherapy With Anti-angiogenic Therapy for Pulmonary Resectable Metastases of Osteosarcoma [NCT03742193] | Phase 2 | 43 participants (Anticipated) | Interventional | 2019-08-11 | Active, not recruiting | ||
| A Randomized, Parallel Control, Exploratory Trial to Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in Subjects With Advanced or Metastatic of the Non-small Cell Lung Cancer (NSCLC) [NCT03256721] | Phase 2 | 37 participants (Actual) | Interventional | 2017-08-16 | Terminated(stopped due to Due to the enrollment was slow and exceeded the expected enrollment time) | ||
| Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Patients Failed in First-line Chemotherapy: A Phase II Study [NCT03251417] | Phase 2 | 11 participants (Actual) | Interventional | 2017-09-10 | Terminated(stopped due to Because PD-1 antibodies had been proved to be a standard second-line treatment in esophageal cancer, the potential benefit of present intervention is under re-evaluation.) | ||
| A Single-arm, Multicenter Clinical Study of Evaluating Camrelizumab Combined With SOX and/or Apatinib in the Treatment of Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma [NCT04792515] | Phase 2 | 67 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Phase II Single-arm Clinical Study of Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed +Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC [NCT04425135] | Phase 2 | 59 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
| A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma [NCT03116555] | Phase 2 | 37 participants (Anticipated) | Interventional | 2017-04-05 | Recruiting | ||
| A Multicenter Clinical Study of Carralizumab Combined With Albumin Paclitaxel and Apatinib Mesylate in the Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma [NCT05653817] | 60 participants (Anticipated) | Interventional | 2023-01-31 | Not yet recruiting | |||
| A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction [NCT02409199] | Phase 2/Phase 3 | 66 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study. [NCT03163381] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-04-11 | Recruiting | ||
| Apatinib Combined With Capecitabine Compared With Apatinib in the Treatment of Advanced Non-resectable Hepatocellular Carcinoma [NCT03114085] | Phase 2 | 170 participants (Anticipated) | Interventional | 2017-05-20 | Not yet recruiting | ||
| A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer [NCT03100955] | Phase 3 | 120 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received [NCT03764293] | Phase 3 | 543 participants (Actual) | Interventional | 2019-06-10 | Active, not recruiting | ||
| Study of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Apatinib in Patients With Hepatocellular Carcinoma Trial [NCT03066557] | 80 participants (Anticipated) | Interventional | 2017-03-15 | Not yet recruiting | |||
| A Randomized, Open-label, Single Dose, Three-period, Six-sequences, Crossover Study of High-fat and Low-fat Meal Effect on the Pharmacokinetics of Apatinib Mesylate in Chinese Healthy Adult Subjects [NCT04341090] | Phase 1 | 42 participants (Actual) | Interventional | 2020-05-13 | Completed | ||
| The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced Esophageal Squamous Cell Carcinoma [NCT03917966] | Phase 2 | 80 participants (Anticipated) | Interventional | 2020-04-07 | Recruiting | ||
| The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Cancer Patients Who Failed Standard First-line Treatment: a Single Arm, Open-label, Phase 2 Study [NCT04415385] | Phase 2 | 48 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | ||
| Maintenance Treatment With Capecitabine Plus Apatinib vs. Apatinib and Observation After First-line XELOX/SOX Chemotherapy for Patients With Advanced Gastric Cancer: a Multicenter, Randomized, Controlled Trial [NCT03598348] | Phase 3 | 288 participants (Anticipated) | Interventional | 2018-01-16 | Recruiting | ||
| A Phase Ib，Open-labeled, Multi-center, Dose-exploring Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib and Fluzoparib in Subjects With Recurrent and Metastatic Triple Negative Breast Cancer [NCT03945604] | Phase 1 | 32 participants (Actual) | Interventional | 2019-06-04 | Completed | ||
| Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer: a Single-arm, Prospective, Multicenter Trial (TAOS-3B-Trial) [NCT05223088] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-10-31 | Recruiting | ||
| Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma：a Single-center, Exploratory Clinical Study [NCT04397770] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-05-31 | Not yet recruiting | ||
| A Multi-center, Open-label, Fixed-sequence Study of Effect of Gefitinib on the Pharmacokinetics of Apatinib Mesylate in Non-squamous, Non-small-cell Lung Cancer Patients [NCT04390984] | Phase 1 | 22 participants (Anticipated) | Interventional | 2020-05-26 | Recruiting | ||
| Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer: HCCSC G05 Trial [NCT04781686] | Phase 2 | 35 participants (Anticipated) | Interventional | 2021-05-14 | Recruiting | ||
| A Single Arm Clinical Phase Ⅱ Study of Apatinib Combined With Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children [NCT04501718] | Phase 2 | 44 participants (Anticipated) | Interventional | 2020-10-28 | Recruiting | ||
| A Single-arm Phase II Study to Evaluate Camrelizumab in Combination With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma [NCT04454905] | Phase 2 | 50 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | ||
| A Single-arm, Open, Multicenter Study of Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma [NCT04012827] | Phase 2 | 108 participants (Anticipated) | Interventional | 2019-08-20 | Recruiting | ||
| Zhejiang Cancer Hospital [NCT04190745] | Phase 2 | 116 participants (Anticipated) | Interventional | 2019-11-29 | Recruiting | ||
| A Phase II, Single-Arm, Open-Label, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Apatinib in Patients With Refractory Malignant Ascites [NCT03020979] | Phase 2 | 120 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
| Efficacy and Safety of Apatinib Added to Docetaxel and Cisplatin Neoadjuvant Therapy for Patients With Breast Cancer: a Randomized, Parallel Controlled Phase II Trial [NCT03580395] | Phase 2/Phase 3 | 200 participants (Anticipated) | Interventional | 2017-06-01 | Enrolling by invitation | ||
| The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer [NCT03154983] | Phase 2 | 48 participants (Anticipated) | Interventional | 2017-05-20 | Recruiting | ||
| A Prospective, Single-arm, Phase II Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib-Mesylate Tablets and Camrelizumab for Injec [NCT04191889] | Phase 2 | 47 participants (Anticipated) | Interventional | 2020-04-13 | Recruiting | ||
| A Phase II Clinical Trial Study on Apatinib and 5-Fu Combination Regimen in the Treatment of Advanced Colorectal Cancer Patients [NCT03210064] | Phase 2 | 42 participants (Anticipated) | Interventional | 2017-05-04 | Recruiting | ||
| Chemotherapy Combined With Apatinib and PD-1 Monoclonal Antibody for Second-line or Above Treatment of Advanced Gastric Cancer-A Prospective, Single-arm, Open, Phase II Study [NCT05025033] | Phase 2 | 30 participants (Actual) | Interventional | 2019-05-30 | Completed | ||
| A Phase II Clinical Trial of Tucidinostat in Combination With Apatinib in Patients With Relapsed or Refractory Osteosarcoma [NCT06125171] | Phase 2 | 46 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Exploratory Study on the Efficacy and the Safety of mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer [NCT03365765] | Phase 3 | 63 participants (Actual) | Interventional | 2018-02-12 | Completed | ||
| Single Center, Single Arm, Open Study, to Explore and Evaluate Treatment of Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma [NCT03251443] | Phase 2 | 34 participants (Actual) | Interventional | 2017-08-08 | Completed | ||
| A Study of Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer [NCT03050411] | Phase 1 | 30 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) [NCT03046979] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Apatinib for Advanced Soft Tissue Sarcoma Patients After Failure of Traditional Therapy: an One-armed, Phase 2, Open-label, Multicenter Prospective Trial [NCT03104335] | Phase 2 | 0 participants (Actual) | Interventional | 2017-04-01 | Withdrawn(stopped due to Not enough patients) | ||
| [NCT02509806] | Phase 2/Phase 3 | 48 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| The Randomized, Controlled Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Lung Adenocarcinoma Patients With Wild-Type EGFR [NCT02493582] | Phase 2 | 400 participants (Anticipated) | Interventional | 2015-07-31 | Active, not recruiting | ||
| PD-1 Inhibitors (Camrelizumab) Combined With VEGF Inhibitors (Apatinib) for Locally Advanced dMMR/MSI-H Colorectal Cancer: an Open-label, Multi-center, Phase II Clinical Trial [NCT04715633] | Phase 2 | 53 participants (Actual) | Interventional | 2020-12-01 | Active, not recruiting | ||
| A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells [NCT03428425] | Phase 2 | 38 participants (Anticipated) | Interventional | 2018-02-28 | Not yet recruiting | ||
| Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer: A Randomized Controlled Trial [NCT03298074] | Phase 2 | 60 participants (Anticipated) | Interventional | 2017-10-31 | Not yet recruiting | ||
| An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric [NCT03285906] | Phase 2/Phase 3 | 30 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | ||
| Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies. [NCT03384511] | Phase 4 | 38 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| The Effectivity and Toxicity of Methylsulfonic Apatinib for Extensively Pre-treated Advanced Sarcoma: a Multicentric Retrospective Study in China [NCT03491371] | 56 participants (Actual) | Interventional | 2015-06-01 | Completed | |||
| Induction Therapy of Camrelizumab Combined With Apatinib Mesylate for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (the IMplus Study) [NCT04440917] | Phase 2 | 32 participants (Anticipated) | Interventional | 2020-06-03 | Recruiting | ||
| Single Arm, Exploratory and Open Clinical Trial of Second-line Therapy With Apatinib Mesylate in Advanced Cholangiocarcinoma [NCT03521219] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-02-07 | Recruiting | ||
| A Randomized Clinical Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients [NCT03511703] | Phase 2 | 40 participants (Anticipated) | Interventional | 2018-05-01 | Not yet recruiting | ||
| A Phase II, Open-Label, Multi-Centre Study of Camrelizumab Plus Apatinib As Consolidation Therapy in Patients With Locally Advanced, Unresectable NSCLC, Who Have Not Progressed Following Definitive, Platinum-Based Chemoradiation Therapy [NCT04749394] | Phase 2 | 42 participants (Anticipated) | Interventional | 2021-03-17 | Recruiting | ||
| A Study of Combined Treatment of Apatinib With Docetaxel as Post Second-line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) [NCT03416231] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| Clinical Study of Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC After Failure of Platinum-based Double-drug Therapy [NCT03411967] | Phase 2 | 20 participants (Anticipated) | Interventional | 2018-02-01 | Not yet recruiting | ||
| A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases [NCT03127319] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-07-03 | Recruiting | ||
| Camrelizumab in Combination With Apatinib Plus NK Cell in Patients With Advanced Hepatocellular Carcinoma (CAN): A First-line, Phase-II, Single-arm Trial [NCT05171309] | Phase 2 | 35 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma [NCT03424291] | Phase 2 | 60 participants (Anticipated) | Interventional | 2017-07-05 | Recruiting | ||
| A Phase II Clinical Trial of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer [NCT03397199] | Phase 2 | 120 participants (Anticipated) | Interventional | 2018-01-09 | Recruiting | ||
| Single Arm, Exploratory and Open Phase II Clinical Trial of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer [NCT03389087] | Phase 2 | 60 participants (Anticipated) | Interventional | 2017-11-29 | Active, not recruiting | ||
| A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) [NCT04446091] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2020-07-01 | Recruiting | ||
| A Prospective, One-arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma With a High Risk of Recurrence [NCT04701060] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-01-26 | Recruiting | ||
| Precision Treatment of Refractory Triple Negative Breast Cancer Based on Molecular Subtyping --FUSCC-TNBC- Umbrella Trial [NCT03805399] | Phase 1/Phase 2 | 140 participants (Anticipated) | Interventional | 2018-10-18 | Recruiting | ||
| Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Apatinib as a Single Agent in Advanced NSCLC Who Failed to at Least Two Lines Systemic Treatment, or Were Not Amendable to Receive the Second-line Standard Therapy [NCT02515435] | Phase 2 | 40 participants (Anticipated) | Interventional | 2015-01-01 | Active, not recruiting | ||
| Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer [NCT03334591] | Phase 2 | 60 participants (Anticipated) | Interventional | 2017-10-01 | Recruiting | ||
| The Randomized, Controlled, Multicenter Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer [NCT02485015] | Phase 2 | 80 participants (Actual) | Interventional | 2015-06-30 | Active, not recruiting | ||
| A Prospective Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma [NCT03320629] | Phase 2 | 80 participants (Anticipated) | Interventional | 2017-11-01 | Recruiting | ||
| Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors [NCT03243643] | Phase 1 | 80 participants (Anticipated) | Interventional | 2017-08-08 | Recruiting | ||
| Apatinib Treatment for Advanced Esophagus Cancer ,One-armed，Exploratory，Openting , Clinical Trail. [NCT03170310] | Phase 2 | 60 participants (Anticipated) | Interventional | 2017-02-21 | Recruiting | ||
| An Open, Multi-center, Phase Ⅱ Clinical Study of Fluzoparib Combined With Apatinib or Fluzoparib in the Treatment of Metastatic Castration-resistant Prostate Cancer [NCT04869488] | Phase 2 | 93 participants (Actual) | Interventional | 2021-07-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||